Drugs Dermatol. 2024;(Suppl 1) IL17/23 axis in psoriasis supports the development of new targeted therapies. Front Immunol. 2024;2024
Interleukin 17 family (IL17 family) is a family of pro-inflammatory cystine knot cytokines. U.S. Food and Drug Administration. . Retrieved
IL17 Blockers Ixekizumab (Taltz) Brodalumab(Siliq) Secukinumab (Cosentyx) Bimekizumab (Bimzelx) – IL-17A and IL-17F
by K Takami 2024 Cited by 1Inappropriate drug concentration and irregular frequency of drug administration are known anti-IL12/23, or anti-IL17 drugs: a 15-year
Conclusions Both anti-IL17 and anti-IL23 appeared to be effective on scalp psoriasis; in particular patients treated with anti-IL17 drugs reached a faster significant reduction of the lesions; on
IL17 Blockers Ixekizumab (Taltz) Brodalumab(Siliq) Secukinumab (Cosentyx) Bimekizumab (Bimzelx) – IL-17A and IL-17F
by L Potestio 2024 Cited by 1Currently, 4 anti-IL17 (secukinumab, ixekizumab, bimekizumab and brodalumab) and 3 anti-IL23 (guselkumab, risankizumab and tildrakizumab) have
Biologic anti-IL17 drugs in erythrodermic psoriasis. Falco, Alessandro. First. Writing - Original Draft Preparation. ;Mugheddu, Cristina. Second. Data Curation.
The most promising future drugs in PsA include 9 molecules: three IL23 inhibitors, two IL17 inhibitors and four JAK inhibitors.
Comments